🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07664228
Recruiting Observational

I-FABP as a Predictor of Gastrointestinal Involvement in Pediatric IgA Vasculitis

NCT07664228 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-05-15
Last updated
2026-06-24

Condition(s) studied

IgA VasculitisGastrointestinal Involvement

Investigational drug(s) / intervention(s)

Plasma I-FABP Measurement

Plasma I-FABP Measurement: Blood samples are collected and plasma I-FABP levels are measured to evaluate gastrointestinal involvement in pediatric IgA vasculitis.

Study summary

This prospective observational study aims to evaluate plasma intestinal fatty acid-binding protein (I-FABP) levels in children with IgA vasculitis and investigate their association with gastrointestinal involvement. Blood samples will be collected at diagnosis and during follow-up 2-4 weeks later. The study will assess the potential value of plasma I-FABP as a biomarker for gastrointestinal involvement in pediatric IgA vasculitis.

Eligibility

Sex
ALL
Min age
2 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of IgA vasculitis (Henoch-Schönlein purpura) according to EULAR/PRINTO/PRES classification criteria. * Age between 2 and 18 years. * Availability for blood sample collection at diagnosis (baseline visit). * Ability to attend a routine follow-up visit approximately 2-4 weeks after diagnosis. * Parent or legal guardian able and willing to provide written informed consent. Exclusion Criteria: * Refusal of informed consent by the parent/legal guardian. * Inability to obtain a baseline blood sample. * Inability to complete study follow-up procedures.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Bursa City Hospital Bursa Bursa Recruiting

More Bursa City Hospital trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07664228 on ClinicalTrials.gov ↗ ← All trials in Turkey